4461
DKS Co.Ltd.
第一工業製薬
- Industry
- Chemicals
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
59,140
Mar 2022
62,672
Mar 2023
65,081
Mar 2024
63,118
Mar 2025
73,255
Operating profit(million JPY)
Mar 2021
4,485
Mar 2022
4,626
Mar 2023
1,186
Mar 2024
2,077
Mar 2025
5,351
Operating profit margin(%)
Mar 2021
7.58
Mar 2022
7.38
Mar 2023
1.82
Mar 2024
3.29
Mar 2025
7.3
Profit before tax(million JPY)
Mar 2021
3,759
Mar 2022
4,179
Mar 2023
224
Mar 2024
2,343
Mar 2025
5,194
Profit(million JPY)
Mar 2021
2,563
Mar 2022
2,492
Mar 2023
-407
Mar 2024
1,174
Mar 2025
2,585
Total assets(million JPY)
Mar 2021
85,033
Mar 2022
86,469
Mar 2023
85,025
Mar 2024
94,537
Mar 2025
97,113
Cash and cash equivalents(million JPY)
Mar 2021
11,531
Mar 2022
12,151
Mar 2023
9,051
Mar 2024
15,947
Mar 2025
16,556
Cash flows from operating activities(million JPY)
Mar 2021
4,955
Mar 2022
5,520
Mar 2023
724
Mar 2024
7,091
Mar 2025
7,528
Cash flows from investing activities(million JPY)
Mar 2021
-3,804
Mar 2022
-2,700
Mar 2023
-2,883
Mar 2024
-2,008
Mar 2025
-2,138
Cash flows from financing activities(million JPY)
Mar 2021
255
Mar 2022
-2,336
Mar 2023
-1,030
Mar 2024
1,646
Mar 2025
-5,045
Return on equity(%)
Mar 2021
7.7
Mar 2022
7
Mar 2023
-1.1
Mar 2024
3.3
Mar 2025
6.9
Equity ratio(%)
Mar 2021
40.7
Mar 2022
42.5
Mar 2023
40.4
Mar 2024
38.9
Mar 2025
39.9
Earnings per share(JPY per share)
Mar 2021
251.97
Mar 2022
244.81
Mar 2023
-41.87
Mar 2024
122.81
Mar 2025
270.08
Net assets per share(JPY per share)
Mar 2021
3,405.28
Mar 2022
3,610.31
Mar 2023
3,593.49
Mar 2024
3,839.89
Mar 2025
4,044.52
Dividend per share(JPY per share)
Mar 2021
70
Mar 2022
80
Mar 2023
80
Mar 2024
65
Mar 2025
100
Payout ratio(%)
Mar 2021
27.78
Mar 2022
32.68
Mar 2023
-
Mar 2024
52.93
Mar 2025
37.03
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.